A Single-center, Open-label, Two-treatment Study to Investigate the Effect of ACT-132577 at Steady State on the Pharmacokinetics of Midazolam and Its Metabolite 1-hydroxy Midazolam in Healthy Male Subjects

Trial Profile

A Single-center, Open-label, Two-treatment Study to Investigate the Effect of ACT-132577 at Steady State on the Pharmacokinetics of Midazolam and Its Metabolite 1-hydroxy Midazolam in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Aprocitentan (Primary) ; Midazolam
  • Indications Cardiovascular disorders; Hypertension
  • Focus Pharmacokinetics
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 28 Oct 2016 Status changed from recruiting to completed.
    • 18 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 25 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top